3.2.1.123	2-N-hexadecanoylamino-4-nitrophenyl-O-beta-lactoside + H2O	-	Corynebacterium sp.	N-(2-hydroxy-5-nitrophenyl)hexadecanamide + beta-lactose	-	?	361202	
3.2.1.123	2-N-hexadecanoylamino-4-nitrophenyl-O-beta-lactoside + H2O	derivative possessing an N-acyl chain, 4-nitrophenyllactoside chromogenic substrate C16ampNPLac	Rhodococcus sp.	N-(2-hydroxy-5-nitrophenyl)hexadecanamide + beta-lactose	-	?	361202	
3.2.1.123	4-methylumbelliferyl beta-D-glucoside + H2O	-	Cryptococcus neoformans	4-methylumbelliferone + beta-D-glucose	-	?	364701	
3.2.1.123	4-methylumbelliferyl beta-D-glucoside + H2O	-	Cryptococcus neoformans H99	4-methylumbelliferone + beta-D-glucose	-	?	364701	
3.2.1.123	4-nitrophenyl alpha-D-glucoside + H2O	low activity	Cryptococcus neoformans	4-nitrophenol + alpha-D-glucose	-	?	431382	
3.2.1.123	4-nitrophenyl alpha-D-glucoside + H2O	low activity	Cryptococcus neoformans H99	4-nitrophenol + alpha-D-glucose	-	?	431382	
3.2.1.123	4-nitrophenyl beta-D-glucoside + H2O	high activity	Cryptococcus neoformans	4-nitrophenol + beta-D-glucose	-	?	364700	
3.2.1.123	4-nitrophenyl beta-D-glucoside + H2O	high activity	Cryptococcus neoformans H99	4-nitrophenol + beta-D-glucose	-	?	364700	
3.2.1.123	7-nitro-2,1,3-benzoxadiazole-pentanol + digalactosyldiacylglycerol	transglycosylation	Rhodococcus equi	?	-	?	408236	
3.2.1.123	alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi	ceramide + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc	-	?	446971	
3.2.1.123	alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi 103S	ceramide + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc	-	?	446971	
3.2.1.123	alpha-L-fucosyl-(1->2)-ganglioside GM1a + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	431583	
3.2.1.123	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi	ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc	-	?	446984	
3.2.1.123	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	preferred substrate	Rhodococcus sp. M-777	ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc	-	?	446984	
3.2.1.123	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi 103S	ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc	-	?	446984	
3.2.1.123	beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi	ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc	-	?	447202	
3.2.1.123	beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus sp. M-777	ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc	-	?	447202	
3.2.1.123	beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi 103S	ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc	-	?	447202	
3.2.1.123	beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi	ceramide + beta-D-Gal-(1->4)-Glc	-	?	447206	
3.2.1.123	beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus sp. M-777	ceramide + beta-D-Gal-(1->4)-Glc	-	?	447206	
3.2.1.123	beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi 103S	ceramide + beta-D-Gal-(1->4)-Glc	-	?	447206	
3.2.1.123	beta-D-GalNAc-(1->3)-alpha-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O	-	Rhodococcus equi	ceramide + beta-D-GalNAc-(1->3)-alpha-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc	-	?	447209	
3.2.1.123	blood group A type 1 heptaglycosylceramide + H2O	-	Rhodococcus sp.	?	-	?	416729	
3.2.1.123	blood group A type 2 heptaglycosylceramide + H2O	-	Rhodococcus sp.	?	-	?	416730	
3.2.1.123	C6-7-nitro-2,1,3-benzoxadiazole-glucosylceramide + H2O	-	Cryptococcus neoformans	?	-	?	431724	
3.2.1.123	C6-7-nitro-2,1,3-benzoxadiazole-glucosylceramide + H2O	-	Cryptococcus neoformans H99	?	-	?	431724	
3.2.1.123	D-erythro-dihydrosphingosine + H2O	-	Rhodococcus sp.	?	-	?	391736	
3.2.1.123	D-erythro-sphingosine + H2O	-	Rhodococcus sp.	?	-	?	391738	
3.2.1.123	Forssman glycolipid + H2O	isoform EGCase I exhibits 25.2% activity with this substrate	Rhodococcus equi	?	-	?	431864	
3.2.1.123	Fucalpha(1->3)GalNAcalpha(1->3)[Fucalpha(1->2)]Galbeta(1->4)Glcbeta(1-1)ceramide + H2O	84% of the activity with galactosylcerebroside	Rhodococcus sp.	Fucalpha(1->3)GalNAcalpha(1->3)[Fucalpha(1->2)]Galbeta(1->4)Glc + ceramide	-	?	361199	
3.2.1.123	Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. Gb3Cer	Rhodococcus sp.	Galalpha(1-4)Galbeta(1-4)Glc + ceramide	-	?	361180	
3.2.1.123	Galalpha1-6Galalpha1-6Galbeta1-6Galbeta1-1'ceramide + H2O	most rapidly hydrolyzed	Rhodococcus equi	ceramide + Galalpha1-6Galalpha1-6Gal	-	?	392013	
3.2.1.123	Galalpha1-6Galbeta1-3-diacylglycerol + H2O	-	Rhodococcus equi	?	-	?	409433	
3.2.1.123	Galalpha1-6Galbeta1-6Galbeta1-1'ceramide + H2O	-	Rhodococcus equi	ceramide + Galalpha1-6Galbeta1-6Gal	-	?	392014	
3.2.1.123	Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glc	-	?	381911	
3.2.1.123	Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris 105	ceramide + Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glc	-	?	381911	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Bacillus sp. (in: Bacteria)	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Cyanea nozakii	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Aiptasia sp.	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Entacmaea sp.	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Cellana sp.	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Meretrix sp.	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Ruditapes sp.	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Marphysa sp.	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris 105	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381912	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381913	
3.2.1.123	Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris 105	ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	381913	
3.2.1.123	Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + Galbeta(1,4)Glc	-	?	381914	
3.2.1.123	Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris 105	ceramide + Galbeta(1,4)Glc	-	?	381914	
3.2.1.123	Galbeta(1,6)Galbeta(1,6)Galbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100, no reaction	Hydra vulgaris	?	-	?	381915	
3.2.1.123	Galbeta(1,6)Galbeta(1,6)Galbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100, no reaction	Hydra vulgaris 105	?	-	?	381915	
3.2.1.123	Galbeta(1,6)Galbeta(1,6)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + Galbeta(1,6)Galbeta(1,6)Glc	-	?	381916	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM1	Corynebacterium sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM1	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM1	Cyanea nozakii	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM1	Condylactis sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GM1a	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	as active as lactosylceramide	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	cholera toxin receptor	Corynebacterium sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM1	Rhodococcus sp. C9	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM1	Rhodococcus sp. G-74-2	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	as active as lactosylceramide	Rhodococcus sp. G-74-2	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361181	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + methanol	i.e. GM1	Cyanea nozakii	?	products may be attributed to GM-1 oligosaccharide II3NeuAcGgOse4 and methyl-GM-1 oligosaccharide methyl-II3NeuAcGgOse4	?	361182	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide 4-nitrobenzo-2-oxy-1,3-diazole + H2O	i.e. NBD-GM1	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + 4-nitrobenzo-2-oxy-1,3-diazole ceramide	-	?	361203	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide 4-nitrobenzo-2-oxy-1,3-diazole + H2O	i.e. NBD-GM1	Rhodococcus sp. C9	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + 4-nitrobenzo-2-oxy-1,3-diazole ceramide	-	?	361203	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD1b	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361184	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD1b	Cyanea nozakii	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361184	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	good substrate for strain M-777, weak substrate for strain C9	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361184	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD1b	Rhodococcus sp. C9	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361184	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	good substrate for strain M-777, weak substrate for strain C9	Rhodococcus sp. C9	Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361184	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	weak substrate	Cyanea nozakii	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide	-	?	361183	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	as active as lactosylceramide	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide	-	?	361183	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. asialo-GM1	Rhodococcus sp.	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide	-	?	361183	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. asialo-GM1	Cyanea nozakii	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide	-	?	361183	
3.2.1.123	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. asialo-GM1	Rhodococcus sp. C9	Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide	-	?	361183	
3.2.1.123	Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	weak substrate	Cyanea nozakii	Galbeta(1-4)Glc + ceramide	-	?	361185	
3.2.1.123	Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. lactosylceramide	Rhodococcus sp.	Galbeta(1-4)Glc + ceramide	-	?	361185	
3.2.1.123	Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. lactosylceramide	Cyanea nozakii	Galbeta(1-4)Glc + ceramide	-	?	361185	
3.2.1.123	Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. lactosylceramide	Cyanea nozakii	Galbeta(1-4)Glc + ceramide	i.e. lactose	r	361185	
3.2.1.123	Galbeta(1-6)Galbeta(1-6)Galbeta(1-1)ceramide + H2O	i.e. neogalactosylceramide, 77% of the activity with lactosylceramide	Rhodococcus sp.	Galbeta(1-6)Galbeta(1-6)Gal + ceramide	-	?	361186	
3.2.1.123	Galbeta1-1'-ceramide + H2O	-	Rhodococcus equi	?	-	?	409437	
3.2.1.123	Galbeta1-6Galbeta1-1'-ceramide + H2O	highest transglycosylation efficiency	Rhodococcus equi	?	-	?	409438	
3.2.1.123	Galbeta1-6Galbeta1-1'ceramide + H2O	-	Rhodococcus equi	ceramide + Galbeta1-6Galbeta	-	?	392015	
3.2.1.123	Galbeta1-6Galbeta1-6Galbeta1-1'-ceramide + H2O	-	Rhodococcus equi	ceramide + Galbeta1-6Galbeta1-6Gal	-	?	392016	
3.2.1.123	Galbeta1-6Galbeta1-6Galbeta1-1'-ceramide + H2O	-	Rhodococcus equi	?	-	?	409439	
3.2.1.123	Galbeta1-6Galbeta1-6Galbeta1-6Galbeta1-1'-ceramide + H2O	-	Rhodococcus equi	?	-	?	409440	
3.2.1.123	GalNAcalpha(1,4)GalNAcbeta(1,4)GlcNAcbeta(1,3)Manbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + GalNAcalpha(1,4)GalNAcbeta(1,4)GlcNAcbeta(1,3)Manbeta(1,4)Glc	-	?	381927	
3.2.1.123	GalNAcalpha(1-3)GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. Gb5Cer	Rhodococcus sp.	GalNAcalpha(1-3)GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide	-	?	361187	
3.2.1.123	GalNAcbeta(1,3)Galalpha(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + GalNAcbeta(1,3)Galalpha(1,4)Galbeta(1,4)Glc	-	?	381928	
3.2.1.123	GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	weak substrate	Rhodococcus sp.	GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide	-	?	361188	
3.2.1.123	GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. Gb4Cer	Rhodococcus sp.	GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide	-	?	361188	
3.2.1.123	GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	-	Rhodococcus sp.	GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361189	
3.2.1.123	GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GM2, 94% of the activity with lactosylceramide	Rhodococcus sp.	GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361189	
3.2.1.123	GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. Gg3Cer	Rhodococcus sp.	GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide	-	?	361190	
3.2.1.123	ganglioside + H2O	-	Rhodococcus sp.	?	-	?	392025	
3.2.1.123	ganglioside fucosyl-GM1 + H2O	100% hydrolyzed by EGCase I and 19% hydrolyzed by EGCase II	Rhodococcus sp.	?	-	?	405224	
3.2.1.123	ganglioside Gb3Cer + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	431865	
3.2.1.123	ganglioside Gb4Cer + H2O	isoform EGCase I exhibits 33.9% activity with this substrate	Rhodococcus equi	?	-	?	431866	
3.2.1.123	ganglioside GbOse3Cer + H2O	73% hydrolyzed by EGCase I and 24% hydrolyzed by EGCase II	Rhodococcus sp.	?	-	?	405225	
3.2.1.123	ganglioside GbOse4Cer + H2O	34% hydrolyzed by EGCase I and 7% hydrolyzed by EGCase II	Rhodococcus sp.	?	-	?	405226	
3.2.1.123	ganglioside GbOse5Cer + H2O	25% hydrolyzed by EGCase I and 6.5% hydrolyzed by EGCase II	Rhodococcus sp.	?	-	?	405227	
3.2.1.123	ganglioside GD1a + H2O	100% hydrolyzed by EGCase I and II	Rhodococcus sp.	?	-	?	115514	
3.2.1.123	ganglioside GD1a + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	115514	
3.2.1.123	ganglioside GD1a + H2O	100% hydrolyzed by EGCase I and II	Rhodococcus sp. M-750	?	-	?	115514	
3.2.1.123	ganglioside GD1b + H2O	87% hydrolyzed by EGCase I and 74% hydrolyzed by EGCase II	Rhodococcus sp.	?	-	?	115515	
3.2.1.123	ganglioside GD1b + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	115515	
3.2.1.123	ganglioside GD1b + H2O	87% hydrolyzed by EGCase I and 74% hydrolyzed by EGCase II	Rhodococcus sp. M-750	?	-	?	115515	
3.2.1.123	ganglioside GD3 + H2O	100% hydrolyzed by EGCase I and II	Rhodococcus sp.	?	-	?	381942	
3.2.1.123	ganglioside GD3 + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	381942	
3.2.1.123	ganglioside GD3 + H2O	100% hydrolyzed by EGCase I and II	Rhodococcus sp. M-750	?	-	?	381942	
3.2.1.123	ganglioside GM1 + H2O	100% hydrolyzed by EGCase I and II	Rhodococcus sp.	?	-	?	115517	
3.2.1.123	ganglioside GM1 + H2O	100% hydrolyzed by EGCase I and II	Rhodococcus sp. M-750	?	-	?	115517	
3.2.1.123	ganglioside GM1a + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	431867	
3.2.1.123	ganglioside GM3 + H2O	isoform EGCase I exhibits 100% activity with this substrate	Rhodococcus equi	?	-	?	115516	
3.2.1.123	ganglioside TGC + H2O	66% hydrolyzed by EGCase III	Rhodococcus sp.	?	-	?	405228	
3.2.1.123	GlcA4Me-beta(1,4)[GalNAc-Me-alpha(1,3)]Fucalpha(1,4)GlcNAcbeta(1,2)Manalpha(1,3)[Xylbeta(1,2)]Manbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + GlcA4Me-beta(1,4)[GalNAc-Me-alpha(1,3)]Fucalpha(1,4)GlcNAcbeta(1,2)Manalpha(1,3)[Xylbeta(1,2)]Manbeta(1,4)Glc	-	?	381952	
3.2.1.123	Glcbeta1-6Galbeta1-1'-ceramide + H2O	-	Rhodococcus equi	?	-	?	409516	
3.2.1.123	GlcNAcalpha1-2Fucalpha1-3Manbeta1-4Glcbeta1-1'-ceramide + H2O	-	Rhodococcus sp.	ceramide + GlcNAcalpha1-2Fucalpha1-3Manbeta1-4Glc	-	?	409517	
3.2.1.123	GlcNAcbeta(1-2)Manalpha(1-3)Manbeta(1-4)Glcbeta(1-1)ceramide + H2O	35% of the activity with lactosylceramide	Rhodococcus sp.	GlcNAcbeta(1-2)Manalpha(1-3)Manbeta(1-4)Glc + ceramide	-	?	361191	
3.2.1.123	globotetraosylceramide + H2O	-	Rhodococcus sp.	?	-	?	189986	
3.2.1.123	globotriaosylceramide + H2O	-	Rhodococcus sp.	?	-	?	370962	
3.2.1.123	glucosylceramide + H2O	isoform EGCase I exhibits 6.7% activity with this substrate	Rhodococcus equi	?	-	?	189989	
3.2.1.123	glycosphingolipid + H2O	strongly resistant to hydrolysis by endoglycoceramidase II in comparison with endoglycoceramidase I	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	glycosphingolipids readily hydrolyzed, globo-type (slowly)	Corynebacterium sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	ganglio-type	Corynebacterium sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	ganglio-type	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	GM3	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	neutral and acidic in presence of 0.1% Triton X-100, lacto-type	Corynebacterium sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	neutral and acidic in presence of 0.1% Triton X-100, lacto-type	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	GM2	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	glycosphingolipids, overview	Corynebacterium sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	cell-surface glycosphingolipids of erythrocytes, horse-erythrocyte cell-surface GM3 and guinea pig erythrocyte cell-surface Gg3Cer	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	glycosphingolipid + H2O	release of glycans from the ceramide moieties of glycosphingolipids by endoglycoceramidase II treatment in order to analyze structures of glycosphingolipids in normal human colorectal epithelial cells, and characteristic alterations of oligosaccharide structures in malignant transformation	Rhodococcus sp.	?	-	?	361204	
3.2.1.123	GM1 ganglioside + H2O	-	Rhodococcus sp. M-777	GM1-aglycan + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc	-	?	447579	
3.2.1.123	isoglobotetraosylceramide + H2O	-	Rhodococcus sp.	?	-	?	417114	
3.2.1.123	isoglobotriaosylceramide + H2O	-	Rhodococcus sp.	?	-	?	417115	
3.2.1.123	lactosylceramide + H2O	isoform EGCase I exhibits 29.9% activity with this substrate	Rhodococcus equi	?	-	?	189987	
3.2.1.123	Manalpha(1-3)Manbeta(1-4)Glcbeta(1-1)ceramide + H2O	88% of the activity with lactosylceramide	Rhodococcus sp.	Manalpha(1-3)Manbeta(1-4)Glc + ceramide	-	?	361200	
3.2.1.123	Manbeta(1-4)Glcbeta(1-1)ceramide + H2O	93% of the activity with lactosylceramide	Rhodococcus sp.	Manbeta(1-4)Glc + ceramide	-	?	361201	
3.2.1.123	monogalactosylceramide + H2O	-	Rhodococcus equi	ceramide + D-galactose	-	?	392668	
3.2.1.123	additional information	no substrate: GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide, i.e. Gb4Cer	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: sulfatides	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: sphingomyelins	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: gala-type glycosphingolipids	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	enzyme has transglycosylation activity, 1-hexanol is best acceptor for GM1, 1-pentanol and 1-heptanol are also used	Corynebacterium sp.	?	-	?	89	
3.2.1.123	additional information	enzyme prefers lactosides with acylamide structures over simple n-alkyl lactosides as substrates	Corynebacterium sp.	?	-	?	89	
3.2.1.123	additional information	enzyme prefers lactosides with acylamide structures over simple n-alkyl lactosides as substrates	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: cerebrosides	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: glycoglycerolipids	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O, i.e. Gb3Cer	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: N-linked glycoproteins	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	no substrate: O-linked glycoproteins	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	hardly attacks linkages between monosaccharides and ceramides, i.e. cerebrosides, or between oligosaccharides and diacylglycerol, i.e. glycoglycerolipids	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	enzyme from strain C9 hydrolyzes b-series gangliotetraosylceramides more slowly than M-777 enzyme, whereas both enzymes hydrolyse a-series gangliosides and neutral glycosphingolipids to the same extent	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	reduces glycosphingolipid levels in HL60 cells	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	removes glycosphinolipid-sugar chains from the cell surface of living cells	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	enzyme destroys the cholera toxin receptor GM1 on the cell surface of HELA cells and therefore reduces the amount of cholera toxin attached to the cells	Corynebacterium sp.	?	-	?	89	
3.2.1.123	additional information	reduces ganglioside content in membrane fractions and intact cells of A431 cells	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	acidic glycosphingolipids from primary colonic adenocarcinoma and hepatic metastasis, releases glycans from the ceramide moiety	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	does not hydrolyze ganglio-, globo-, or lacto-series glycosphingolipids	Rhodococcus equi	?	-	?	89	
3.2.1.123	additional information	Fucalpha(1-2)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3)Galbeta(1-4))Glcbeta(1-1)ceramide is strongly resistant to hydrolysis by the enzyme	Sus scrofa	?	-	?	89	
3.2.1.123	additional information	both rhodococcal EGCases I and II efficiently hydrolyze ganglio-series glycosphingolipids, whereas EGCase I hydrolyzes globo-series-glycosphingolipids much faster than EGCase II. The glycan chain from fucosyl-GM1 can be prepared by using EGCase I. EGCase III stands alone to hydrolyze 6-gala-series glycosphingolipids. All EGCases are not able to hydrolyze sphingomyelin and sulfatide	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	synthesis of sugar-sphingolipid glycosidic linkages. Extent of ganglioside synthesis is proportional to enzyme concentration and length of incubation time	Rhodococcus sp.	?	-	?	89	
3.2.1.123	additional information	EGALC specifically hydrolyzes the Galbeta1-1'-ceramide linkage in 6-Gal series glycosphingolipids	Rhodococcus equi	?	-	?	89	
3.2.1.123	additional information	no activity towards Galbeta1-6Glcbeta1-1'-ceramide, Galbeta1-4Galbeta1-1'-ceramide, Galalpha1-1'ceramide, Glcbeta1-1'-ceramide, Galbeta1-4Glcbeta1-1'ceramide, Galalpha1-4Galbeta1-4Glcbeta1-1'-ceramide, and Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-4Glcbeta1-1'-ceramide	Rhodococcus equi	?	-	?	89	
3.2.1.123	additional information	almost no hydrolysis is observed for isoform EGCase II with alpha-L-fucosyl-(1->2)-ganglioside GM1a, ganglioside Gb3Cer, and ganglioside Gb4Cer. Isoform EGCase I shows no activity with ganglioside GM4, trigalactosylceramide, sulfatide, and sphingomyelin	Rhodococcus equi	?	-	?	89	
3.2.1.123	additional information	for transglycosylation activity, isoform EGCase I prefers alkanols with a relatively long carbon chain such as pentanol and hexanol as an acceptor substrate	Rhodococcus equi	?	-	?	89	
3.2.1.123	additional information	no activity with beta-D-Glc-(1<->1')-ceramide, beta-D-Gal-(1<->1')-ceramide, beta-D-GalNAc-(1->3)-alpha-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide and alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide	Rhodococcus sp. M-777	?	-	?	89	
3.2.1.123	additional information	specifically hydrolyzes the glycosidic linkage between the oligosaccharide and the ceramide moieties of various glycosphingolipids. No activity with beta-D-Glc-(1<->1')-ceramide and beta-D-Gal-(1<->1')-ceramide	Rhodococcus equi	?	-	?	89	
3.2.1.123	additional information	specifically hydrolyzes the glycosidic linkage between the oligosaccharide and the ceramide moieties of various glycosphingolipids. No activity with beta-D-Glc-(1<->1')-ceramide and beta-D-Gal-(1<->1')-ceramide	Rhodococcus equi 103S	?	-	?	89	
3.2.1.123	additional information	enzyme has transglycosylation activity, 1-hexanol is best acceptor for GM1, 1-pentanol and 1-heptanol are also used	Corynebacterium sp. A-809	?	-	?	89	
3.2.1.123	additional information	enzyme from strain C9 hydrolyzes b-series gangliotetraosylceramides more slowly than M-777 enzyme, whereas both enzymes hydrolyse a-series gangliosides and neutral glycosphingolipids to the same extent	Rhodococcus sp. C9	?	-	?	89	
3.2.1.123	additional information	both rhodococcal EGCases I and II efficiently hydrolyze ganglio-series glycosphingolipids, whereas EGCase I hydrolyzes globo-series-glycosphingolipids much faster than EGCase II. The glycan chain from fucosyl-GM1 can be prepared by using EGCase I. EGCase III stands alone to hydrolyze 6-gala-series glycosphingolipids. All EGCases are not able to hydrolyze sphingomyelin and sulfatide	Rhodococcus sp. M-750	?	-	?	89	
3.2.1.123	additional information	no substrate: N-linked glycoproteins	Rhodococcus sp. G-74-2	?	-	?	89	
3.2.1.123	additional information	no substrate: O-linked glycoproteins	Rhodococcus sp. G-74-2	?	-	?	89	
3.2.1.123	additional information	hardly attacks linkages between monosaccharides and ceramides, i.e. cerebrosides, or between oligosaccharides and diacylglycerol, i.e. glycoglycerolipids	Rhodococcus sp. G-74-2	?	-	?	89	
3.2.1.123	NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc	-	?	382413	
3.2.1.123	NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100, most favoured substrate	Hydra vulgaris	ceramide + NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha-2,3]Gal-beta(1,4)Glc	-	?	382414	
3.2.1.123	NeuAcalpha(2,3)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O	37°C, pH 3.0, 0.2% (w/v) Triton X-100	Hydra vulgaris	ceramide + NeuAcalpha(2,3)Galbeta(1,4)Glc	-	?	382415	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	-	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361192	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD, 93% of the activity with lactosylceramide	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361192	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD1a	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361192	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	-	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361193	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	good substrate for strain M-777, weak substrate for strain C9	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361193	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GT1b	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361193	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GT1b	Cyanea nozakii	NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361193	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	93% of the activity with lactosylceramide	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide	-	?	361195	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM3	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide	-	?	361195	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. GM3	Cyanea nozakii	NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide	-	?	361195	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	-	Corynebacterium sp.	NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide	-	?	361194	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	-	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide	-	?	361194	
3.2.1.123	NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	i.e. sialylparagloboside, as active as lactosylceramide	Rhodococcus sp.	NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide	-	?	361194	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GT, 81% of the activity with lactosylceramide	Rhodococcus sp.	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361198	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	-	Rhodococcus sp.	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361196	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	good substrate for strain M-777, weak substrate for strain C9	Rhodococcus sp.	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361196	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GQ1b	Rhodococcus sp.	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361196	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GQ1b	Cyanea nozakii	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide	-	?	361196	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD3	Rhodococcus sp.	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide	-	?	361197	
3.2.1.123	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O	GD3	Cyanea nozakii	NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide	-	?	361197	
3.2.1.123	non-acid glycosphingolipids of human gastric epithelium + H2O	-	Rhodococcus sp.	?	-	?	417421	
3.2.1.123	oligoglycosylglucosyl-(1<->1)-ceramide + H2O	-	Rhodococcus equi	ceramide + oligoglycosylglucose	-	?	431086	
3.2.1.123	porcine brain ganglioside-1 + H2O	-	Sus scrofa	?	-	?	393290	
3.2.1.123	porcine brain ganglioside-3 + H2O	-	Sus scrofa	?	-	?	393291	
3.2.1.123	porcine brain ganglioside-4 + H2O	-	Sus scrofa	?	-	?	393292	
3.2.1.123	porcine brain ganglioside-5 + H2O	-	Sus scrofa	?	-	?	393293	
3.2.1.123	resorufin + beta-D-glucose + H2O	highest catalytic efficiency	Cryptococcus neoformans	resorufin-beta-D-glucoside	-	?	432346	
3.2.1.123	resorufin + beta-D-glucose + H2O	highest catalytic efficiency	Cryptococcus neoformans H99	resorufin-beta-D-glucoside	-	?	432346	
3.2.1.123	trigalactosylceramide + H2O	-	Rhodococcus equi	?	-	?	410403